Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.5
4.2
Journals
Toxins
Special Issues
Bee Venom Therapies from Basic Science to Clinical Fields
share announcement

Bee Venom Therapies from Basic Science to Clinical Fields

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Animal Venoms".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 7801

Special Issue Editors

Dr. Byung-Cheul Shin

E-Mail Website
Guest Editor
Department of Korean Medicine Rehabilitation, Pusan National University Korean Medicine Hospital, Yangsan, Kyungnam 50612, Korea
Interests: evidence-based medicine; traditional Korean/Chinese medicine; spine & joint diseases; pain medicine;
Dr. Soo-Hyun Sung

E-Mail Website
Guest Editor
Department of Policy Development, National Institute of Korean Medicine Development, Seoul, Republic of Korea
Interests: bee venom
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Bee toxin has historically been used for various pain conditions such as arthritis, rheumatoid diseases, and musculoskeletal pain for therapeutic purposes in many countries. Bee venom contains many bioactive compounds which exert pharmacological effects presenting analgesic, anti-inflammatory, anti-cancer, and immune-stimulant effects. There were several systematic reviews on the effectiveness and safety of bee venom therapy in the treatment of rheumatoid arthritis, musculoskeletal pain, shoulder pain, and post-stroke shoulder pain. This means bee venom has been used towards therapeutic aims and clinical trials, especially randomized controlled trials, which have been conducted in the effort of determining the effectiveness and safety of bee venom in clinical fields.

However, many concerns should be addressed with regard to bee venom use in the clinical field. How should it be standardized for therapeutic dosage and how can this be used with good safety? What is the mechanism of the effects of bee venom and its compounds? How can we maximize its positive effects?

This Special Issue will focus on the clinical use of bee venom and bee venom acupuncture in the clinical field, but not limited to clinical trials. This includes basic research such as animal experimental studies (in vivo and in vitro), ingredients, surveys on its use, as well as reviews and systematic reviews.

Dr. Byung-Cheul Shin
Dr. Soo-Hyun Sung
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bee venom
  • bee toxin
  • bee venom acupuncture
  • randomized clinical trial
  • systematic review
  • melittin
  • adolapin
  • apamin
  • Phospholipase A2
  • safety

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 4901 KiB  
Article
Wasp Venom Ameliorates Scopolamine-Induced Learning and Memory Impairment in Mice
by Ji Hyeong Chae, Jisun Oh, Ji Sun Lim, Yoon Ah Jeong, Hyun Seok Yun, Chan Ho Jang, Hyo Jung Kim and Jong-Sang Kim
Toxins 2022, 14(4), 256; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins14040256 - 04 Apr 2022
Cited by 4 | Viewed by 2152
Abstract
This study investigated the effects of wasp venom (WV) from the yellow-legged hornet, Vespa velutina, on scopolamine (SCO)-induced memory deficits in mice, as well as the antioxidant activity in HT22 murine hippocampal neuronal cells in parallel comparison with bee venom (BV). The [...] Read more.
This study investigated the effects of wasp venom (WV) from the yellow-legged hornet, Vespa velutina, on scopolamine (SCO)-induced memory deficits in mice, as well as the antioxidant activity in HT22 murine hippocampal neuronal cells in parallel comparison with bee venom (BV). The WV was collected from the venom sac, freeze-dried. Both venoms exhibited free radical scavenging capabilities in a concentration-dependent manner. In addition, the venom treatment enhanced cell viability at the concentrations of ≤40 µg/mL of WV and ≤4 µg/mL of BV in glutamate-treated HT22 cells, and increased the transcriptional activity of the antioxidant response element (ARE), a cis-acting enhancer which regulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2)-downstream antioxidant enzymes. Concurrently, WV at 20 µg/mL significantly increased the expression of a key antioxidant enzyme heme oxygenase 1 (HO-1) in HT22 cells despite no significant changes observed in the nuclear level of Nrf2. Furthermore, the intraperitoneal administration of WV to SCO-treated mice at doses ranged from 250 to 500 µg/kg body weight ameliorated memory impairment behavior, reduced histological injury in the hippocampal region, and reduced oxidative stress biomarkers in the brain and blood of SCO-treated mice. Our findings demonstrate that WV possess the potential to improve learning and memory deficit in vivo while further study is needed for the proper dose and safety measures and clinical effectiveness. Full article
(This article belongs to the Special Issue Bee Venom Therapies from Basic Science to Clinical Fields)
►▼ Show Figures

Figure 1

12 pages, 6662 KiB  
Article
Apamin Enhances Neurite Outgrowth and Regeneration after Laceration Injury in Cortical Neurons
by Hyunseong Kim, Jin Young Hong, Junseon Lee, Wan-Jin Jeon and In-Hyuk Ha
Toxins 2021, 13(9), 603; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13090603 - 28 Aug 2021
Cited by 5 | Viewed by 2397
Abstract
Apamin is a minor component of bee venom and is a polypeptide with 18 amino acid residues. Although apamin is considered a neurotoxic compound that blocks the potassium channel, its neuroprotective effects on neurons have been recently reported. However, there is little information [...] Read more.
Apamin is a minor component of bee venom and is a polypeptide with 18 amino acid residues. Although apamin is considered a neurotoxic compound that blocks the potassium channel, its neuroprotective effects on neurons have been recently reported. However, there is little information about the underlying mechanism and very little is known regarding the toxicological characterization of other compounds in bee venom. Here, cultured mature cortical neurons were treated with bee venom components, including apamin, phospholipase A2, and the main component, melittin. Melittin and phospholipase A2 from bee venom caused a neurotoxic effect in dose-dependent manner, but apamin did not induce neurotoxicity in mature cortical neurons in doses of up to 10 µg/mL. Next, 1 and 10 µg/mL of apamin were applied to cultivate mature cortical neurons. Apamin accelerated neurite outgrowth and axon regeneration after laceration injury. Furthermore, apamin induced the upregulation of brain-derived neurotrophic factor and neurotrophin nerve growth factor, as well as regeneration-associated gene expression in mature cortical neurons. Due to its neurotherapeutic effects, apamin may be a promising candidate for the treatment of a wide range of neurological diseases. Full article
(This article belongs to the Special Issue Bee Venom Therapies from Basic Science to Clinical Fields)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 868 KiB  
Systematic Review
Incidence Rate of Bee Venom Acupuncture Related Anaphylaxis: A Systematic Review
by Seong-Hwan Ko, Hyeon-Muk Oh, Do-Young Kwon, Jae-Eun Yang, Byung-Jun Kim, Hyun-Ju Ha, Eun-Jin Lim, Min-Seok Oh, Chang-Gue Son and Eun-Jung Lee
Toxins 2022, 14(4), 238; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins14040238 - 26 Mar 2022
Cited by 8 | Viewed by 2572
Abstract
Background: Bee venom acupuncture (BVA) is an effective treatment method for various diseases. Bee venom, however, can cause adverse effects, even rarely including life-threatening anaphylaxis, so safety-related evidence is required. In this study, we systematically estimated the incidence rate of anaphylaxis in response [...] Read more.
Background: Bee venom acupuncture (BVA) is an effective treatment method for various diseases. Bee venom, however, can cause adverse effects, even rarely including life-threatening anaphylaxis, so safety-related evidence is required. In this study, we systematically estimated the incidence rate of anaphylaxis in response to BVA. Methods: We searched eight databases (MEDLINE (Pubmed), EMBASE, Cochrane Central Register of Controlled, KISS, KMBASE, Koreamed, OASIS, and NDSL) and systematically reviewed the articles that met the inclusion/exclusion criteria. Results: Among 225 potentially relevant articles, 49 were selected for this study. The overall incidence rate of anaphylaxis in response to BVA was 0.045% (95% CI 0.028–0.062). Women (0.083%, 95% CI 0.010–0.157) showed a higher incidence rate than men (0.019%, 95% CI −0.018 to 0.055), while the incidence for patients who had a skin test conducted (0.041%, 95% CI 0.011–0.072) was not significantly different compared to that obtained for patients for which there was no information about a skin test (0.047%, 95% CI 0.026–0.067). The publication year affected the incidence rate: it was highest before 1999 (1.099%, 95% CI −1.043 to 3.241), lower between 2000 and 2009 (0.049%, 95% CI 0.025–0.073), and lowest between 2010 and 2021 (0.037% 95% CI 0.014–0.060). Conclusions: In this study, we provide reference data about risk size and factors of BVA-related anaphylaxis, which is essentially required for BVA application in clinics. Full article
(This article belongs to the Special Issue Bee Venom Therapies from Basic Science to Clinical Fields)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop